Patient-Controlled Subcutaneous Analgesia with Hydromorphone versus Oral Oxycontin for Opioid Titration of Cancer Pain: A Prospective Multicenter Randomized Trial

References

• van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn JKessels AG et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449. doi:10.1093/annonc/mdm056
   PubMed Web of Science ®Google Scholar
• Lin R, Zhu J, Luo Y, et al. Intravenous patient-controlled analgesia versus oral opioid to maintain analgesia for severe cancer pain: a randomized phase II trial. J Natl Compr Canc Netw. 2022;20(9):1013–1021. doi:10.6004/jnccn.2022.7034
   PubMed Web of Science ®Google Scholar
• Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain. 2007;11(8):823–830. doi:10.1016/j.ejpain.2007.01.003
   PubMed Web of Science ®Google Scholar
• Syrjala KL, Jensen MP, Mendoza ME, et al. Psychological and behavioral approaches to cancer pain management. J Clin Oncol. 2014;32(16):1703–1711. doi:10.1200/JCO.2013.54.4825
   PubMed Web of Science ®Google Scholar
• Lin R, Lin S, Feng S, et al. Comparing patient-controlled analgesia versus non-pca hydromorphone titration for severe cancer pain: a randomized phase III trial. J Natl Compr Canc Netw. 2021;19(10):1148–1155. doi:10.6004/jnccn.2020.7699
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–68. doi:10.1016/S1470-2045(12)70040-2
   PubMed Web of Science ®Google Scholar
• Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29:166–191. doi:10.1093/annonc/mdy152
   Google Scholar
• Sun Y, Wei H, Yu M, et al. Rapid titration with oral sustained-release morphine plus subcutaneous morphine in a multi-center, randomized control study of cancer patients with moderate to severe cancer pain. Jpn J Clin Oncol. 2022;52(11):1303–1310. doi:10.1093/jjco/hyac128
   PubMed Web of Science ®Google Scholar
• Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998;16(10):3222–3229。. doi:10.1200/JCO.1998.16.10.3222
   PubMed Web of Science ®Google Scholar
• Jun G, Jing L, Bo L, et al. Effect of hydrochloride oxycodone controlled-release tablets with dose titration for moderate or severe cancer pain. Chin J Cancer Prev Treat. 2017;15:1319–1322.
   Google Scholar
• Pan H, Shen P, Shu Q, et al. Efficacy and safety of sustained-release oxycodone compared with immediate-release morphine for pain titration in cancer patients: a multicenter, open-label, randomized controlled trial (SOCIAL). Medicine. 2019;98:e15505. doi:10.1097/MD.0000000000015505
   PubMedGoogle Scholar
• Feng W, Wang Y, Ran F. Ran F et al.The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: a retrospective cohort study. Front Med. 2022;9:918468. doi:10.3389/fmed.2022.918468
   Web of Science ®Google Scholar
• Song EK, Shim H, Han H-S. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (Oros ®) hydromorphone in opioid-naive cancer patients: results of the Korean south west oncology group study. Pain Res Manag. 2015;20(6):293–299. doi:10.1155/2015/458389
   PubMed Web of Science ®Google Scholar
• Oldenmenger WH, Lieverse PJ, Janssen PJ, Taal W, van der Rijt CC, Jager A. Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. Support Care Cancer. 2012;20(8):1639–1647. doi:10.1007/s00520-011-1254-1.
   PubMed Web of Science ®Google Scholar
• Bartz L, Klein C, Seifert A, et al. Subcutaneous administration of drugs in palliative care: results of a systematic observational study. J Pain Symptom Manag. 2014;48(4):540–547. doi:10.1016/j.jpainsymman.2013.10.018
   PubMed Web of Science ®Google Scholar
• Johannessen LEF. The commensuration of pain: how nurses transform subjective experience into objective numbers. Soc Sci Med. 2019;233:38–46. doi:10.1016/j.socscimed.2019.05.042
   PubMed Web of Science ®Google Scholar
• Yu SY, Wang JJ, Huang YG, et al. Managing pain in patients with cancer: the Chinese good pain management experience. J Glob Oncol. 2016;3(5):583–595. doi:10.1200/JGO.2016.005686
   PubMedGoogle Scholar
• Swarm RA, Youngwerth JM, Agne JL, et al. NCCN clinical practice guidelines in oncology: adult cancer pain. Version 1.2022. Accessed March 1, 2022. To view the most recent version, visit NCCN.org.
   Google Scholar
• Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. J Pain Symptom Manage. 2017;53(3):630–643. doi:10.1016/j.jpainsymman.2016.10.370
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.Accessed 14, Oct 2019.
   Google Scholar
• Guo KK, Deng CQ, Lu GJ, et al. Comparison of analgesic effect of oxycodone and morphine on patients with moderate and advanced cancer pain: a meta-analysis. BMC Anesthesiol. 2018;18(1):132. doi:10.1186/s12871-018-0583-8
   PubMedGoogle Scholar
• Zhou J, Wang Y, Jiang G. Gang Jiang.Oxycodone versus morphine for cancer pain titration: a systematic review and pharmacoeconomic evaluation. PLoS One. 2020;15(4):e0231763. doi:10.1371/journal.pone.0231763
   PubMed Web of Science ®Google Scholar
• Liang J, Chen L, Yang S, et al. A 12-hour rapid titration method for cancer pain: a randomized, controlled, open-label study. Ann Palliat Med. 2021;10(1):88–96. doi:10.21037/apm-20-2336
   PubMed Web of Science ®Google Scholar
• Wan C-F, Meng Q-Z, Wang Y-W. Yan-Wei Wang et al.Patient-controlled subcutaneous analgesia using sufentainil or morphine in home care treatment in patients with stage III-IV cancer: a multicenter randomized controlled clinical trial. Cancer Med. 2020;9(15):5345–5352. doi:10.1002/cam4.3194
   PubMed Web of Science ®Google Scholar
• Sousa AM, de Santana Neto J, Guimaraes GMN, et al. Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. Support Care Cancer. 2014;22(3):795–801. doi:10.1007/s00520-013-2036-8
   PubMed Web of Science ®Google Scholar
• University of Texas MD Anderson Cancer Center Cancer Pain – Adult,version 12; 2020.
   Google Scholar
• Gonul S, Ayse B, Yanik F. Fazli Y.The comparison of two different techniques of remifentanil administration during implantable vascular access device procedures. J Perianesth Nurs. 2021;36(6):664–671. doi:10.1016/j.jopan.2021.02.007
   PubMed Web of Science ®Google Scholar
• Gibney M, Xue Z, Swinney M, et al. Reduced silent occlusions with a novel catheter infusion set (BD FlowSmart): results from two open-label comparative studies. Diabetes Technol Ther. 2016;18(3):136–143. doi:10.1089/dia.2015.0342
   PubMed Web of Science ®Google Scholar
• Oosten AW, Oldenmenger WH, Mathijssen RH, et al. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain. 2015;16(10):935–946. doi:10.1016/j.jpain.2015.05.006
   PubMed Web of Science ®Google Scholar
• Xiao X, Chu Q, Chen Y. Patient-controlled subcutaneous analgesia with hydromorphone versus oral oxycodone for opioid titration of cancer pain: a prospective multicenter randomized trial. J Clin Oncol. 2023;41(16):12124. doi:10.1200/JCO.2023.41.16_suppl.12124
   Web of Science ®Google Scholar